Radar · Industry landscape · the United States
Life Sciences Landscape of the United States
23,666 Life Sciences companies in the United States, in one picture: who is hiring, who is raising money, who founded them, where they are based, what the news is about, which skills employers want and where the research is going. Updated August 2026.
23,666companies tracked
$505.2Bdisclosed funding
1,579hiring right now
23,605events · 24 months
245,045news articles · 12 months
Who leads Life Sciences in the United States
Shows 23,666 U.S. life‑sciences firms, highlighting the 1,579 currently hiring and the 9,070 that have disclosed a funding round; top hiring firms include Insulet, Brooks Automation and ResMed.
open roles
Hiring now
ranked by live open roles
- 01
Insulet13last posted Aug 2026
- 02
Brooks Automation13last posted Aug 2026
- 03
ResMed12last posted Jul 2026
- 04
Haemonetics12last posted Jul 2026
- 05
HearUSA12last posted Jul 2026
- 06
Intuitive Surgical12last posted Jul 2026
- 07
Veeva Systems12last posted Jun 2026
- 08
AssistRx12last posted Jun 2026
1,579 companies hiring · 56 posted in the last 30 days
disclosed funding
Most funded
disclosed totals, all rounds
- 01
BeiGene$5.1BPost IPO · Jul 2020
- 02
Moderna$4.2BGrant (prize money) · Jan 2025
- 03
Celgene$3.1BPost IPO · Feb 2018
- 04
Verily$2.8BSeries D · Mar 2026
- 05
Novavax$2.7BPost IPO · Sep 2023
- 06
Invitae$2.5BPost IPO · Apr 2021
- 07
GRAIL$2.3BPost IPO · Oct 2025
- 08Amyris$2.2BPost IPO · Dec 2022
9,070 companies with disclosed rounds · $505.2B total
revenue
Revenue leaders
official filings first, else latest snapshot
- 01
Aptar Pharma$3.8Bsnapshot Dec 2025
- 02
Alnylam$3.7BFY2021 filing
- 03
Sonic$3.7BFY2020 filing
- 04
- 05
Bio Rad$2.6Bsnapshot Dec 2025
- 06
Biogen$2.5BFY2020 filing
- 07
Agilent$1.8BFY2022 filing
- 08
Edwards Lifesciences$1.6BFY2018 filing
619 companies with a revenue figure
headcount
Largest teams
ranked by tracked headcount
- 01
- 02
Dentsply Sirona15,000tracked employees
- 03
carefusion14,000tracked employees
- 04
ICU Medical14,000tracked employees
- 05
Etex13,500tracked employees
- 06
Guidant13,000tracked employees
- 07
- 08
KEYENCE10,580tracked employees
2,385 companies with headcount data
share of events
Share of voice
share of all tracked sector news events, 24 months
- 01
23andMe0.7%216 tracked events
- 02
- 03
Illumina0.6%195 tracked events
- 04
Dexcom0.5%163 tracked events
- 05
BioMarin Pharmaceutical0.5%161 tracked events
- 06
Dynavax0.5%152 tracked events
- 07
Sarepta0.4%133 tracked events
- 08
32,856 tracked events across 2,975 companies
articles
In the news
Prism news coverage, last 12 months
- 01
- 02
NICO3,414articles in the window
- 03
College Park2,241articles in the window
- 04
Nano1,479articles in the window
- 05
- 06
Wheaton1,262articles in the window
- 07
- 08
Blue Tech1,203articles in the window
1,000 of these companies drew sector coverage in the window
Radar
See all 23,666 Life Sciences companies in the United States
Filter by funding, headcount, hiring and location, and export the list.
How the Life Sciences ecosystem in the United States grew, 2016–2025
Lists the number of companies founded each year from 2016 to 2025, with the highest count of 1,184 in 2016 and 127 in 2025.
Companies founded / year
new Life Sciences companies in the United States
20162025
peak 1,184 in 2016
Companies raising / year
with a disclosed round that year
20162025
peak 1,868 in 2020
Disclosed funding / year
sum of disclosed rounds (USD)
20162025
peak $55.3B in 2021
Where Life Sciences companies in the United States are based
Hub 01
San Diego
933 Life Sciences companies
20% of the Life Sciences companies across these hubs
933companies
$38.7Bdisclosed funding
69hiring now
Hub 02
San Francisco
925 Life Sciences companies
20% of the Life Sciences companies across these hubs
925companies
$46.4Bdisclosed funding
102hiring now
Hub 03
New York City
709 Life Sciences companies
15% of the Life Sciences companies across these hubs
709companies
$18.7Bdisclosed funding
51hiring now
Hub 04
Cambridge
637 Life Sciences companies
14% of the Life Sciences companies across these hubs
637companies
$56.6Bdisclosed funding
90hiring now
Hub 05
Boston
581 Life Sciences companies
13% of the Life Sciences companies across these hubs
581companies
$24.6Bdisclosed funding
56hiring now
Hub 06
Los Angeles
323 Life Sciences companies
7% of the Life Sciences companies across these hubs
323companies
$4.9Bdisclosed funding
30hiring now
Hub 07
Houston
269 Life Sciences companies
6% of the Life Sciences companies across these hubs
269companies
$3.6Bdisclosed funding
18hiring now
Hub 08
Austin
258 Life Sciences companies
6% of the Life Sciences companies across these hubs
258companies
$3.5Bdisclosed funding
20hiring now
generated artwork
The Life Sciences market map of the United States: what these companies actually do
Breaks down product sub‑categories, showing enterprise tech (14,552 firms) as the largest, and outlines common revenue models such as physical commerce (11,293 firms).
- Enterprise Tech14,552 companies · $450B raised · 1,251 hiring
- Medical Devices5,358 companies · $109.7B raised · 478 hiring
- Biopharmaceuticals4,752 companies · $262.4B raised · 366 hiring
- Healthtech3,751 companies · $71.8B raised · 341 hiring
- Enterprise Software3,269 companies · $63.5B raised · 251 hiring
- Deep Tech3,205 companies · $106.9B raised · 291 hiring
- Consumer Digital3,138 companies · $34.7B raised · 181 hiring
- In Vitro Diagnostics1,146 companies · $29B raised · 77 hiring
- SaaS1,145 companies · $22.1B raised · 127 hiring
- Nutritional Formula992 companies · $3B raised · 46 hiring
- Healthtech SaaS935 companies · $19.9B raised · 105 hiring
- IoT in Healthcare679 companies · $14B raised · 59 hiring
Monetization
How Life Sciences companies make money
How many companies earn revenue each way. Plenty use more than one model, so the counts add up to more than the sector.
Physical Commerce11,293
E-Commerce - Product9,534
Subscription6,484
Fee-For-Service4,106
Commission on Transaction606
Advertising464
E-Commerce - Service259
Sponsorship37
Funding, M&A and the deals moving Life Sciences in the United States
Counts 23,605 corporate events over the past two years, including 6,741 earnings releases, 3,830 funding rounds and 2,260 mergers and acquisitions.
Earnings 6,741Funding 3,830Leadership 3,725M&A 2,260IPO 1,708Announcement 1,562Contracts 784Lawsuit 755Assets 584Regulatory 520
- M&AEsperion Therapeutics (Nasdaq: ESPR) (Esperion), a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies, and ARCHIMED, a leading investment firm focused exclusively on healthcare industries, have announced that they have entered into a definitive agreement under which funds managed by ARCHIMED will acquire Esperion in a transaction valued at up to approximately US$1.1 billion in total equity value (including a non-tradeable contingent value right (CVR) tied to the achievement of certain commercial-based milestones).2026-05-05
- M&ACandid is choosing the M&A route instead, opting to accept a $2 billion buyout offer that gives UCB the biotech’s pipeline of T cell engagers for immune disorders.2026-05-05
- M&AUCB SA agreed to pay $2 billion up front to acquire bispecific T-cell engager (TCE)-maker Candid Therapeutics Inc. and lead BCMA/CD3 TCE asset cizutamig (CND-106), continuing big pharma’s spree for China-made autoimmune assets in 2026.2026-05-04
- M&APresident and CEO Alexander Hardy said the Amicus deal closed last week and described it as “a new and exciting chapter” that increases portfolio diversification.2026-05-04
- FundingWith these funds, combined with net proceeds from a recent $80 million public offering, the company reports cash and cash equivalents balance of approximately $64.6 million as of March 31, 2026.2026-05-04
- FundingCNS Pharmaceuticals Inc. (NASDAQ: CNSP) has announced a private placement expected to generate approximately $22.5 million in gross proceeds, according to a press release.2026-05-04
- FundingCabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA ), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten offering of 51,725,000 shares of common stock. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $150 million.2026-05-04
- FundingTechcyte has now raised a total of $50.4M in total equity funding and is backed by Mayo Clinic, Van Tuyl Companies, and Zoetis.2026-05-04
- M&APrudential Financial Inc. bought a new stake in Viking Therapeutics in the 2nd quarter valued at about $196,000.2026-05-04
- IPOEvommune had issued 9,375,000 shares in its IPO on November 6th. The total size of the offering was $150,000,000 based on an initial share price of $16.00.2026-05-04
Mergers and acquisitions
Deals from the last 24 months where a Life Sciences company in the United States was the buyer or the one bought, newest first. “Undisclosed” means the price was never published — not that the deal was worth nothing.
| Acquirer | Target | Deal value | Status | Date |
|---|---|---|---|---|
| undisclosed | Announced | 2026-06-25 | ||
| $1.9B | Terminated | 2026-06-25 | ||
| $256M | Announced | 2026-05-19 | ||
| UCB S.A. | $2B | Announced | 2026-05-05 | |
| $1.1B | Announced | 2026-05-05 | ||
| $230k | Completed | 2026-05-04 |
Who is listing, hiring leaders, launching and winning work
Details specific events like IPO filings, leadership changes, product launches and contract wins for the sector’s companies.
IPO pipeline
91 companies listed or filing · last 24 months
EvommuneIPO · NYSE · EVMN · 15 reportsMay 2026
Aura BiosciencesIPO · Nasdaq · AURA · 1 reportMay 2026
Avalyn PharmaIPO · Nasdaq Global Select Market · AVLN · 5 reportsApr 2026
senseonicsFollow-on Offering · NYSE · SENS · 1 reportApr 2026
Seaport TherapeuticsIPO · Nasdaq · SPTX · 2 reportsApr 2026
Intellia TherapeuticsFollow-on Offering · NASDAQ · NTLA · 1 reportApr 2026
AltimmuneFollow-on Offering · NASDAQ · ALT · 1 reportApr 2026
NektarFollow-on Offering · NASDAQ · NKTR · 2 reportsApr 2026
Leadership moves
248 tracked people moves · last 12 months
Bicara TherapeuticsClaire Mazumdar · Appointment → Chief Executive OfficerMay 2026
RejoniJohn Nealon · Appointment → Chief Executive OfficerMay 2026
Guardant HealthCraig Eagle · Resignation — was Chief Medical OfficerMay 2026
Product launches
tracked launches · last 12 months
CheckerspotAlgolein (microalgae-derived oil)Apr 2026
CeresEndura stack (Solid Oxide Fuel Cell Stack)Apr 2026
Lantern PharmawithZeta.ai (AI platform for rare cancer drug discovery)Apr 2026
Mission MightyMeNutty Puffs (Snack)Apr 2026
Cyanotechhigh-purity spirulina extracts (Dietary Supplements)Apr 2026
NU SkinPrysm iO (Handheld wellness device)Apr 2026
Butterfly NetworkAI ultrasound pregnancy tool (AI ultrasound pregnancy tool)Mar 2026
Contract wins
276 customer wins · last 24 months
SCILEX Pharmaceuticalswon Datavault AIApr 2026
Aligos Therapeuticswon Xiamen Amoytop BiotechApr 2026
Lumos Diagnosticswon micro-pakApr 2026
In Silicowon eli lillyMar 2026
Workforce actions
68 companies cutting roles · last 24 months
f5 Therapeuticsscale undisclosed · fundingApr 2026
Rampart Biosciencescale undisclosedApr 2026
Faraday Pharmascale undisclosedApr 2026
Lyra Therapeutics~28 roles reported · cost reductionApr 2026
EveryONE Medicinesscale undisclosed · regulatory frameworkApr 2026
Komodo Health~78 roles reported · IPO market downturnApr 2026
Regulatory & litigation
93 regulatory events · 32 tracked suits · 24 months
BioCrystgranted exclusive licenseMay 2026
Emergent BioSolutionsNo Action Indicated status — U.S. Food & Drug Administration (FDA)Apr 2026
- tesaro v anaptysbioAnticipatory breach and declaratory judgment dispute over license agreement · OngoingApr 2026
- tesaro v AnaptysContract breach · DismissedApr 2026
Earnings pulse
companies reporting results · last 24 months
903 companies reporting7,390 company-quarters trackedbeat 1637miss 881in line 147
Half of these companies grew revenue faster than +16.0%, half slower.
Who is building Life Sciences in the United States
Profiles 14,343 founders and CEOs across 10,682 firms, noting Harvard (387 alumni) and Stanford (378 alumni) as the most frequent alma maters and McKinsey (49) as the top prior employer.
Founders and chief executives12 of 14,343, from the best-funded companies on this page
Granular Insurance, Google, ex-Co-Founder Chronicle, Symantec, Best Buy, Yahoo. University of Oregon BS 1998, San Francisco State University MBA 2006
Ex-Harmony Biosciences, Teva Pharmaceuticals, Cephalon, Pfizer. State University of New York at Plattsburgh BS 1989, Binghamton University MBA 1992
Ex-Navigenics, Affymetrix, Celera Diagnostics, Celera Genomics. Stanford Medical School PhD, Whitehead Institute.
Dante Labs, ex-Affymetrix, ex-Life Technologies, University of Connecticut
Ex-CFO Biosensors International. Brigham Young University BS 1983
repeat founder
Sheffield United Football Club, ex-Illumina. Stanford University BS 2000, MS 2001, PhD 2006
Exact Sciences, ex-Third Wave Technologies, ex-Ge Healthcare, University of Michigan Law School, 1991
repeat founder
Founder Alkermes & Cubist Pharmaceuticals, Chairman Tyr Pharma.
Ex- Thermo Fisher, Luminex, Roche Molecular Systems, Roche Diagnostics, Abbott Diagnostics. University of Wyoming. MBA
Where the founders studied
alma mater on record for 2,655 of 14,343 founders
Harvard University387
Stanford University378
Massachusetts Institute of Technology377
University of Pennsylvania211
University of California (Berkeley)204
Cornell University157
Harvard Business School156
Yale University117
Where they worked before
a previous employer on record for 212 of 14,343 founders
McKinsey49
Microsoft31
Google28
Amazon22
Boston Consulting Group18
Intel18
Apple13
Bain12
Founders flagged as repeat founders
of 12,094 founders with a profile on this page
137
carry a repeat-founder flag
- flagged as repeat founders137
- no repeat-founder flag11,957
Women and men among the founders
first names matched for 12,993 of 14,343 founders
15%
of matched founders are women
- women1,911
- men11,082
Inferred from first names, using 119 million people who state their own gender: a first name counts only where at least 20 of them share it and at least 90% of those share the same gender. The other 1,350 founders go in neither column.
Radar
Look up the people behind Life Sciences companies in the United States
Search founders, executives and operators by company, role and location.
Who funds Life Sciences in the United States
Records 22,828 funding rounds since 2016 from 6,646 investors, with a typical round size of $2.3 million.
| Investor · most active investors since 2016 | Rounds | Led | Latest |
|---|---|---|---|
| HHS | 4667 | 2 | Dec 2025 |
| National Science Foundation | 426 | — | Apr 2026 |
| NIH | 301 | 3 | Apr 2026 |
| Orbimed | 261 | 77 | Apr 2026 |
| RA Capital Management | 245 | 86 | Apr 2026 |
| Y Combinator | 220 | 104 | May 2026 |
| Alexandria | 195 | 27 | Apr 2026 |
| America’s Seed Fund | 192 | — | Jul 2025 |
| Europa | 180 | — | Mar 2024 |
| Arch Venture Partners | 173 | 79 | May 2026 |
Stage mix · rounds since 2016
Seed & Angel4,165
Series A–B6,212
Series C+ / PE2,059
Grants, debt & other10,392
The typical round is $2.3M — half were bigger, half smaller.
The biggest Life Sciences funding rounds in the United States
Highlights the largest disclosed round—MiRus’s $1.5 billion Series D—and lists ten other large recent rounds.
| Company | Round | Size | When | Backers |
|---|---|---|---|---|
| Series Dmega-round | $1.5B | May 2026 | Boston Scientific | |
| Series Bmega-round | $1.2B | Feb 2017 | Arch Venture Partners, Johnson & Johnson Innovation, McKesson Ventures +5 more | |
| Series Dmega-round | $1B | Apr 2024 | Arch Venture Partners, Foresite Labs, F-Prime Capital +10 more | |
| Series Dmega-round | $830M | May 2021 | T. Rowe Price, Silver Lake, Fidelity Investments +8 more | |
| Series Dmega-round | $821M | Jun 2020 | F-Prime Capital, Arch Venture Partners, Flagship Pioneering +8 more | |
| Series Dmega-round | $787M | Mar 2026 | Dimension, DST Global, INCE Capital +4 more | |
| Series Dmega-round | $656.3M | Jul 2022 | ARCHIMED | |
| Series Emega-round | $650M | May 2025 | Founders Fund, Google Ventures, Sequoia Capital +3 more | |
| Series Dmega-round | $600M | May 2022 | Andreessen Horowitz, Founders Fund, Khosla Ventures +6 more | |
| Series Bmega-round | $600M | Oct 2025 | Bain Capital Private Equity, Adage Capital Management, CPP Investments +10 more |
Venture round sizes · 2023–2025
<$1M517
$1–10M985
$10–50M742
$50–250M405
>$250M25
2,674 venture rounds with a disclosed amount in the window.
Fresh cheques · last 6 months
Series D$1.5BMay 2026
Series B$250MMay 2026
Post IPO$187MMay 2026
Series B$122MMay 2026
Series A$97MMay 2026
Series A$48MMay 2026
Series D$41MMay 2026
Post IPO$40MMay 2026
What the news says about Life Sciences in the United States
Aggregates 245,045 news articles from the last year, most often covering COVID‑19 vaccine development, oncology therapies and rare‑disease treatments.
News volume
Life Sciences coverage across United States · articles per quarter
2021Q22026Q1
peak 152,362 in 2025Q1 · 245,045 articles in the last 12 tracked months
Tone of coverage
share of articles by dominant sentiment (positive / neutral / negative)
202120232025
Positive-tone share moved 73% → 75%, negative 26% → 23% across 2021–2025.
What the coverage is about
The subjects that dominate Life Sciences news in United States. The arrow shows whether each one is being written about more or less than a year ago.
- Covid-19 vaccine development and efficacy trials39,155▲+236%
- Oncology and targeted therapy advancements28,440▼-27%
- Covid-19 vaccination campaigns and rollout strategies23,158▲+328%
- Rare disease therapies and orphan drugs22,835▼-27%
- Economy news: inflation rate analysis22,793▲+20%
- Gene therapy and crispr technologies19,287▼-26%
- Drug pricing and reimbursement strategies19,105▲+38%
- Vaccine research and production methods14,227▼-20%
- Macroeconomic policy and global economics13,875▼-48%
- Generic drug development and market trends13,278▲+21%
Most-covered companies · last 12 months
- 7,669
- 3,414
- 2,241
- 1,479
- 1,283
- 1,262
- 1,223
- 1,203
- 1,146
- 1,139
1,000 Life Sciences companies here were named in the news over this period.
Prism
Watch Life Sciences coverage in United States as it happens
Prism follows these subjects story by story — which companies are named, what is said about them and how the tone moves.
Momentum
The words getting louder — and quieter
Which terms are showing up in more stories than a year ago, and which are fading. The percentage is the change in how many articles mention them.
vaccine candidates+252%vaccine trials+228%vaccination campaigns+396%vaccine immunogenicity+270%mass vaccination sites+643%vaccination coverage+650%vaccine effectiveness study+458%angel investors+128%covid-19 vaccine development+461%pandemic vaccine stockpiling+435%
investigational new vaccine-58%cell-based therapies-42%viral vector vaccines-35%cancer biomarkers-36%diagnostic biotechnology-40%
The pressures the press keeps returning to
Three recurring angles in United States Life Sciences coverage, and whether each is getting more attention year on year (through 2025).
Regulatory Risk ▲ rising
290,712 articles touch this dimension · 52.8% critical tone
20212025
signals: core inflation rate, inflation outlook, inflation breakdown
Funding Momentum ▲ rising
102,225 articles touch this dimension · 49.1% critical tone
20212025
signals: angel investors, vaccine candidates, vaccine trials
Growth ▲ rising
175,378 articles touch this dimension · 49.7% critical tone
20212025
signals: gdp acceleration, gdp growth rate, economic output growth
Life Sciences jobs in the United States: who is hiring and what they ask for
Lists 45,131 job postings from 1,627 employers in the past year, with median advertised salary of $88 k and top skills including Excel, AWS, SQL and Python.
45,131postings · last 12 months
62,665postings tracked overall
1,627employers advertising
$88kmedian advertised salary/yr (n=9558)
Demand
The Skills Employers Ask For
What Life Sciences employers in the United States put in their job ads. The bar is how many postings ask for it; the arrow shows whether demand grew or shrank against the year before.
- excel760▲
- aws454▲
- sql363▲
- python356▲
- microsoft office351▲
- word340▲
- outlook308▲
- powerpoint296▲
- agile294▲
- ci/cd261▲
What level are these roles?
Entry723
Intern836
Senior8,380
Lead3,714
Manager13,232
What they pay, by level
- Manager$115k/yr (n=1835)
- Senior$115k/yr (n=1511)
- Lead$125k/yr (n=901)
- Intern$52k/yr (n=48)
- Entry$40k/yr (n=210)
Most advertised titles
- 1,487
- 622
- 287
- 254
- 231
- 225
What Life Sciences research in the United States is working on
Summarizes 6,260 U.S. research papers, of which 3,981 identify opportunities, 646 note common problems and 360 issue cautions.
How this field talks about itself
United States-affiliated Life Sciences papers (gold) against all published research (grey)
Breakthrough32.6% · 26.3%1.2×
Promising31.0% · 37.4%0.8×
Descriptive17.5% · 17.5%≈ par
Problem-identifying9.1% · 9.6%≈ par
Cautionary5.8% · 4.7%1.2×
Comparative2.8% · 3.7%0.8×
How the work is done
Empirical60.0%
Methods-led19.8%
Reviews16.9%
Position pieces3.2%
Theoretical0.1%
How the research reads
88% positive · 7% neutral · 4% negative, across 6,260 papers.
The institutions doing the work · United States
- 87k
- 75k
- 43k
- 38k
- 36k
- 33k
ranked by how often their work is cited
Leading researchers · United States-affiliated work
Daniel Merenstein · Colin Hill · Francisco Guarner · Gregor Reid · Glenn R. Gibson · Ahmad Almilaji · Kalina Szteyn · Evelyn Fein
The most-cited breakthroughs
- U1 snRNP regulates cancer cell migration and invasion in vitro · 7k cites
- Comprehensive molecular profiling of lung adenocarcinoma · 6k cites
- The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets · 5k cites
- Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway · 5k cites
- Circular RNAs are abundant, conserved, and associated with ALU repeats · 5k cites
Common problems researchers identify632 papers · 7 recurring themes
Problems · theme 01
Challenges in Biomanufacturing Technologies
116 papers · 18.4% of this block
→ -0% share2022→2025 share of research on this subject
Researchers highlight technical hurdles in synthetic biology, enzymatic processes, and nanotech for scalable bioproducts.
Biochemical engineering · Synthetic biology · Biomanufacturing · Nanotechnology
“Microbial Enzymes: Tools for Biotechnological Processes”
116 of these papers raise it as a problem
Problems · theme 02
Foodborne Disease and Contamination Risks
99 papers · 15.7% of this block
→ +2% share2022→2025 share of research on this subject
Studies flag rising public‑health threats from mycotoxins, pathogens, and unsafe fresh produce.
Public health · Mycotoxin · Disease · Contamination
“The growing burden of foodborne outbreaks due to contaminated fresh produce: risks and opportunities”
99 of these papers raise it as a problem
Problems · theme 03
Genomic Instability in Cancer
98 papers · 15.5% of this block
▼ -17% share2022→2025 share of research on this subject
Papers discuss mutation patterns, DNA methylation complexities, and metabolic alterations driving tumor progression.
Mutation · Cancer · DNA methylation · Gene
“Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research”
98 of these papers raise it as a problem
Problems · theme 04
Abiotic Stress in Modern Agriculture
96 papers · 15.2% of this block
▲ +24% share2022→2025 share of research on this subject
Works examine genetic engineering and hormone manipulation to improve crop resilience to environmental stresses.
Agriculture · Abiotic stress · Abiotic component · Biotechnology
“Genetic Engineering for Modern Agriculture: Challenges and Perspectives”
96 of these papers raise it as a problem
Problems · theme 05
Micronutrient Deficiencies and Food Science
93 papers · 14.7% of this block
→ +1% share2022→2025 share of research on this subject
Research points to gaps in nutrient biofortification and microbial fermentation for healthier food products.
Micronutrient · Production · Nutrient · Food science
“Improving nutrition through biofortification: A review of evidence from HarvestPlus, 2003 through 2016”
93 of these papers raise it as a problem
Problems · theme 06
Escalating Antibiotic Resistance
70 papers · 11.1% of this block
▲ +10% share2022→2025 share of research on this subject
Authors outline mechanisms and global impact of antimicrobial resistance across clinical and environmental settings.
Antibiotic resistance · Antimicrobial · Antibiotics · Drug resistance
“An overview of the antimicrobial resistance mechanisms of bacteria”
70 of these papers raise it as a problem
Problems · theme 07
Insecticide Resistance and Pest Management
60 papers · 9.5% of this block
▲ +33% share2022→2025 share of research on this subject
Studies reveal growing resistance in vectors and crops, urging new integrated control strategies.
Resistance · Insecticide resistance · Vector · Integrated pest management
“Insecticide Resistance in Mosquitoes: Impact, Mechanisms, and Research Directions”
60 of these papers raise it as a problem
Cautions353 papers · 7 recurring themes
Cautions · theme 01
DNA Repair and Mutation Concerns
87 papers · 24.6% of this block
▼ -20% share2022→2025 share of research on this subject
Investigations caution about unintended genomic instability when targeting repair pathways.
DNA repair · DNA polymerase · DNA damage · Mutation
“Examining the link between chromosomal instability and aneuploidy in human cells”
87 of these papers raise it as a problem
Cautions · theme 02
Immune Modulation Risks in Therapies
64 papers · 18.1% of this block
▼ -18% share2022→2025 share of research on this subject
Works warn of altered B‑cell and T‑cell responses that may increase infection susceptibility.
Antibody · In vivo · Peripheral blood mononuclear cell · Immune system
“Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs”
64 of these papers raise it as a problem
Cautions · theme 03
Food Safety and Nanomaterial Exposure
51 papers · 14.4% of this block
▲ +24% share2022→2025 share of research on this subject
Research advises careful assessment of nanomaterials’ impact on nutrition and consumer health.
Food safety · Raw material · Health benefits · Sugar
“Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters”
51 of these papers raise it as a problem
Cautions · theme 04
Livestock Nutrition and Environmental Trade‑offs
41 papers · 11.6% of this block
→ +2% share2022→2025 share of research on this subject
Analyses highlight potential drawbacks of feed additives on animal performance and methane emissions.
Dairy cattle · Production · Nutrient · Beef cattle
“Impact of tannin-based additives on animal performance and enteric methane emissions in dairy and beef cattle: A meta-analysis”
41 of these papers raise it as a problem
Cautions · theme 05
Genomic Selection Implementation Limits
38 papers · 10.8% of this block
▼ -33% share2022→2025 share of research on this subject
Papers discuss practical challenges and bias risks in applying genomic selection to crops.
Gene · Genomic selection · Selection · Trait
“Genomic Selection for Crop Improvement”
38 of these papers raise it as a problem
Cautions · theme 06
Integrated Pest Management Complexity
37 papers · 10.5% of this block
▲ +25% share2022→2025 share of research on this subject
Studies caution that biological controls may face ecological constraints and resistance development.
PEST analysis · Agriculture · Pest control · Integrated pest management
“The use of fungal entomopathogens as endophytes in biological control: a review”
37 of these papers raise it as a problem
Cautions · theme 07
Antibiotic Use and Resistance Spillover
35 papers · 9.9% of this block
▲ +10% share2022→2025 share of research on this subject
Research highlights how veterinary antibiotic practices can propagate resistance to human pathogens.
Antibiotic resistance · Antibiotics · Antimicrobial · Bacteria
“Multidrug evolutionary strategies to reverse antibiotic resistance”
35 of these papers raise it as a problem
Opportunities3,882 papers · 7 recurring themes
Opportunities · theme 01
Probiotic and Postbiotic Innovations
759 papers · 19.6% of this block
▼ -18% share2022→2025 share of research on this subject
Emerging work explores microbial products for improving human health and animal performance.
Antimicrobial · Fermentation · Bacteria · Antibiotic resistance
“Probiotics, their health benefits and applications for developing healthier foods: a review”
Opportunities · theme 02
Gene Regulation and Cancer Therapy
750 papers · 19.3% of this block
▼ -26% share2022→2025 share of research on this subject
Studies investigate apoptosis modulation and gene knockdown strategies for targeted oncology treatments.
Apoptosis · Downregulation and upregulation · Gene knockdown · Mutant
“PCBP1 binding to single-stranded poly-cytosine motifs enhances cGAS sensing and impairs breast cancer development”
Opportunities · theme 03
Cell‑Based Immunotherapies
513 papers · 13.2% of this block
▼ -28% share2022→2025 share of research on this subject
Research advances antibody targets and T‑cell engineering to enhance anti‑tumor immunity.
Cell culture · T cell · Antigen · Cell
“CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma”
Opportunities · theme 04
Epigenetic Editing for Disease
497 papers · 12.8% of this block
▼ -28% share2022→2025 share of research on this subject
Papers present tools to reshape DNA methylation and chromatin for therapeutic benefit.
DNA repair · DNA damage · DNA methylation · DNA replication
“Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders”
Opportunities · theme 05
Nanotech Molecular Imaging
472 papers · 12.2% of this block
▼ -14% share2022→2025 share of research on this subject
Innovations combine fluorescence and MRI probes for real‑time tracking of biological processes.
In vivo · Fluorescence · Molecular imaging · Nanotechnology
“Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases”
Opportunities · theme 06
Genomic Resources for Crop Breeding
453 papers · 11.7% of this block
▼ -4% share2022→2025 share of research on this subject
Works showcase sequencing and germplasm diversity to accelerate trait improvement.
Germplasm · Selection · Genetic diversity · Trait
“Genotyping‐by‐Sequencing for Plant Breeding and Genetics”
Opportunities · theme 07
RNA‑Based Regulation Strategies
438 papers · 11.3% of this block
▼ -39% share2022→2025 share of research on this subject
Studies focus on mRNA modifications and microRNA pathways to control gene expression.
Messenger RNA · microRNA · Transcription · RNA polymerase II
“m <sup>6</sup> A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation”
Which of these themes are growing fastest
Tracks how the share of world research on various themes has changed between 2022 and 2025.
Problems
how much more (or less) of the world’s research on this subject each theme took up, 2022→2025
gaining sharelosing share
Insecticide Resistance and Pest Management▲+33%
Abiotic Stress in Modern Agriculture▲+24%
Escalating Antibiotic Resistance▲+10%
Foodborne Disease and Contamination Risks▲+2%
Micronutrient Deficiencies and Food Science▲+1%
Challenges in Biomanufacturing Technologies▼-0%
Genomic Instability in Cancer▼-17%
Cautions
how much more (or less) of the world’s research on this subject each theme took up, 2022→2025
gaining sharelosing share
Integrated Pest Management Complexity▲+25%
Food Safety and Nanomaterial Exposure▲+24%
Antibiotic Use and Resistance Spillover▲+10%
Livestock Nutrition and Environmental Trade‑offs▲+2%
Immune Modulation Risks in Therapies▼-18%
DNA Repair and Mutation Concerns▼-20%
Genomic Selection Implementation Limits▼-33%
Opportunities
how much more (or less) of the world’s research on this subject each theme took up, 2022→2025
gaining sharelosing share
Genomic Resources for Crop Breeding▼-4%
Nanotech Molecular Imaging▼-14%
Probiotic and Postbiotic Innovations▼-18%
Gene Regulation and Cancer Therapy▼-26%
Epigenetic Editing for Disease▼-28%
Cell‑Based Immunotherapies▼-28%
RNA‑Based Regulation Strategies▼-39%
Who files Life Sciences patents in the United States
Counts 457,918 patent filings from 2016‑2025 by roughly 8,000 organisations, with Genentech, University of California and Regeneron Pharma as the leading filers.
457,918 filings 2016–20258,000 assigneespeak 51,616 in 2021
Filing momentum
patents published / year
20162025
Who files the most
- Genentech18,078
- UNIV California17,948
- Regeneron Pharma16,082
- Amgen10,495
- Monsanto9,742
- UNIV Pennsylvania8,521
- Harvard College7,460
- UNIV Texas7,378
Prism
Go deeper on Life Sciences research and innovation
Research themes, patent activity and the companies commercialising them, in one place.
Keep going
Track Life Sciences in the United States beyond this page
Radar finds and filters the companies. Prism watches what is being said about them.
About this data: built from Fliar's company, founder, funding, hiring, jobs, news, research and patent trackers, covering the United States. Counts are of companies we track, not of every company that exists. Updated August 2026.
Contact details
Reach this founder through Fliar Radar
Direct contact details for the people on this page are held in Fliar Radar, behind its own access controls.